Klindex

Lower resp tract infections including bronchitis, pneumonia, empyema, & lung abscess; URTI including tonsillitis, pharyngitis, sinusitis, otitis media, & scarlet fever; skin & skin structure infections including inflammatory acne vulgaris, furuncles, cellulitis, impetigo, abscesses, & contaminated wounds, erysipelas & paronychia (panaritium); gynecological infections including endometritis, pelvic cellulitis, post-surgical vag cuff infection, nongonococcal tubo-ovarian abscess, salpingitis & pelvic inflammatory disease in conjunction w/ antibiotic of appropriate gm -ve aerobic spectrum, cervicitis due to Chlamydia trachomatis as monotherapy; intra-abdominal infections including peritonitis & abdominal abscess in conjunction w/ antibiotic of appropriate gm -ve aerobic spectrum; bone & joint infections including acute hematogenous osteomyelitis & septic arthritis; septicemia & endocarditis; dental infections eg, periodontal abscess & periodontitis; Pneumocystis jiroveci (carinii) pneumonia in patients w/ AIDS or in combination w/ primaquine in AIDS patients who are intolerant to or do not respond to conventional treatment. Alternative treatment of multi-drug resistant Plasmodium falciparum infection in combination w/ quinine or amodiaquine.

Adult Serious infections 150-300 mg every 6 hr. More severe infections 300-450 mg every 6 hr. Acne 150 mg every 12 hr. Bacterial vaginosis 300 mg every 12 hr for 7 days. Cervicitis due to Chlamydia trachomatis 450 mg every 6 hr for 10-14 days. Pelvic inflammatory disease (inpatient treatment) 900 mg every 8 hr + an antibiotic w/ an appropriate gm -ve aerobic spectrum IV. Continue w/ oral clindamycin HCl 450 mg every 6 hr to complete 10-14 days total therapy. Prevention of bacterial endocarditis in penicillin-allergic patients 600 mg single dose 30-60 min before procedure. Pneumocystis jiroveci (carinii) pneumonia in patients w/ AIDS 300-450 mg every 6-8 hr + primaquine for 21 days. Alternative treatment of multi-drug resistant Plasmodium falciparum infection 5-10 mg/kg bid + quinine or amodiaquine for at least 5 days.

May be taken with or without food: Take w/ full glass of water to avoid possibility of esophageal irritation.

Hypersensitivity to clindamycin or lincomycin.

Clostridium difficile-associated diarrhea (CDAD). Not to be used in patients w/ nonbacterial infections. Discontinue use if CDAD is suspected or confirmed. Serious allergic reactions/severe skin reactions. Discontinue use & initiate appropriate therapy if hypersensitivity or severe skin reaction occurs. Atopic individuals, as well as in patients w/ history of GI disease, particularly colitis. Concomitant use w/ neuromuscular blocking agents. Not to be used for meningitis. May cause hemolytic reactions w/ primaquine in patients w/ G6PD deficiency. Do blood exam routinely during therapy w/ primaquine to monitor potential hematologic toxicities. Patients w/ severe renal &/or hepatic impairment accompanied by severe metabolic aberrations; monitor serum levels during high-dose therapy. Perform periodic liver & kidney function tests & blood counts during prolonged therapy. Perform surgical drainage & removal of necrotic tissue in combination w/ antibiotic therapy. Prescribing in the absence of a proven or strongly suspected bacterial infection or prophylactic indication may increase risk of antibiotic resistance. Overgrowth of non-susceptible organisms including fungi in long term or repeated use. Determine liver enzyme levels periodically when treating patients w/ severe liver disease. Pregnancy & lactation. Childn ≤16 yr. Elderly.

CDAD & colitis/pseudomembranous colitis, nausea, vomiting, diarrhea, abdominal pain/cramps, tenesmus, flatulence, bloating, anorexia, wt loss, esophagitis, esophageal ulcers; generalized mild to moderate morbilliform-like (maculopapular) skin rashes, rash, urticaria, pruritus, fever, hypotension, anaphylaxis/anaphylactoid reactions; erythema multiforme, SJS; exfoliative & vesiculobullous dermatitis, vesiculobullous rashes, serious cutaneous adverse reaction, TEN, acute generalized exanthematous pustulosis, DRESS; jaundice, hepatic damage, transient increases in serum bilirubin, alkaline phosphatase, AST; azotemia, oliguria, &/or proteinuria, abnormalities in LFTs; vag infection/vaginitis; transient neutropenia (leukopenia), eosinophilia, thrombocytopenia, & agranulocytosis; leukocytoclastic angiitis; polyarthritis; dysgeusia; lymphadenitis.

May enhance neuromuscular blocking actions w/ potential danger of resp depression of neuromuscular blocking agents eg, ether, tubocurarine & pancuronium. May antagonize the bactericidal activity of aminoglycosides. Diminishes the activity of ampicillin in vitro against Staph aureus. Antagonism of bactericidal activity w/ erythromycin. Antagonizes the effect of anticholinesterases neostigmine & physostigmine. May possibly reduce contraceptive effect of estrogens. Inactivate oral typhoid vaccine. Increased coagulation test results (prothrombin time/INR) &/or bleeding w/ vit K antagonists (eg, warfarin, acenocoumarol & fluindione).

Other Antibiotics

J01FF01 - clindamycin ; Belongs to the class of lincosamides. Used in the systemic treatment of infections.

Rx